Hemophilia Market - Forecasts from 2023 to 2028

The hemophilia market is expected to grow at a CAGR of 6.08% from US$11.127 billion in 2021 to US$16.819 billion in 2028.

Hemophilia is a rare disorder in which there are insufficient clotting factors, resulting in improper blood clotting. This results in nosebleeds, pain, edoema, tightness in the joints, and inexplicable bleeding. The growing prevalence of hemophilia among the world population along with its associated adverse effects on individuals is contemplated to boost the hemophilia market. Moreover, the product launches and frequent government approvals for the hemophilia drug along with the favourable policies are further expected to propel the hemophilia market.

Growing Prevalence of Hemophilia Disease

The rising cases of hemophilia worldwide indicate the need for treatment and thus contribute positively to the hemophilia market. For instance, there were 233,577 identified patients with hemophilia in 2021 including 185,318 cases of hemophilia A as per the World Federation of Hemophilia Report 2021. The prevalence rate has increased by 9% from 2020 and 296% between 1999 and 2021 according to the World Federation of Hemophilia. With such a high frequency of hemophilia worldwide, medicines for the condition will be used more frequently, fueling the expansion of the hemophilia market.

Multiple Associated Adverse Effects of Hemophilia

The multiple complications caused by hemophilia indicate the requirement of treatment therapies thereby propelling the hemophilia market. Internal bleeding can injure tissues and organs and is potentially fatal. Some persons with severe hemophilia can experience bleeding into the brain after a minor hit on the head which is a major serious problem. Moreover, internal bleeding may cause agonizing discomfort due to joint pressure. If untreated, internal bleeding regularly can cause joint deterioration or arthritis. Additionally, the immune system reacts badly to the clotting medications used to treat bleeding in some people with severe hemophilia. When this happens, the immune system creates proteins that block the action of the clotting factors, decreasing the efficacy of the medication.

Government Favorable Policies

Several efforts and policies such as approvals by the government in the hemophilia treatment therapies are advancing the hemophilia market. For instance, a gene therapy Roctavian developed by BioMarin Pharmaceutical for hemophilia A was granted approval by the FDA in June 2023. The European Commission approved the first gene therapy in February 2023 for adults with hemophilia B developed by uniQure. Additionally, to improve access to clinical trials for those with bleeding disorders, the Haemophilia Federation of America unveiled a new tool and search function in June 2023.

Rising Research Projects in the Field

The hemophilia disorder is continuously looking for a rise in research projects and clinical trials for advanced treatment thereby propelling the hemophilia market. In May 2023, Pfizer announced the positive Marstacimab results from pivotal phase 3 hemophilia A and B trials. This study showed a significant reduction in annualized bleeding rate compared to prophylaxis and on-demand intravenous regimes. Moreover, in March 2023, the National Haemophilia Foundation will launch Pathway to Cures (P2C), a new $3.5 million venture philanthropy investment fund that aims to have a transformative effect on all inheritable blood illnesses, including hemophilia.

Restraints in the Market

Apart from all the growth drivers, some factors are expected to limit the hemophilia market growth. The hemophilia market is anticipated to be hampered by the high cost of therapy and the general lack of awareness of emerging technology. While gene treatments might offer a novel approach to treating hemophilia, they can be expensive, costing up to $3.5 million for a single dose. Additionally, gene treatments for hemophilia aren't always effective. Moreover, the unknown causes of certain hemophilia represent another restraint in the hemophilia market making it complex to develop and experiment with the therapies.

North America is Expected to Grow Significantly

During the forecast period, the North American region is anticipated to account for a sizeable portion of the hemophilia market. Various factors attributed to such a share are rising hemophilia cases, increasing awareness, and technological advancements. For instance, 1 in 5,000 male babies has hemophilia A. Each year, 400 infants are born with hemophilia A in the US. According to the World Federation of Haemophilia 2021 study, there were 14,816 hemophilia patients in the United States in 2020, including those with hemophilia A (11,790 cases) and hemophilia B (30026 cases). Moreover, National Haemophilia Awareness Month was established to raise awareness of the condition and discover solutions to assist hemophiliacs who might feel helpless to deal with their issues during March each year which also boosts the hemophilia market in the region.

Hemophilia Market Players

• CSL Behring is one of the leading biopharmaceutical companies focused on plasma-derived and recombination therapeutic products. Biostate® for human coagulation factor VIII, Cluviate® for human coagulation factor XII, Cluvot® for factor XIII, and Corifact® for factor XIII Concentrate are some of the hematology products offered by the company.
• Novo Nordisk, founded in 1923 and headquartered in Denmark is one of the leading healthcare companies to develop treatments for serious chronic diseases. The company is exploring innovative long-acting and subcutaneous treatment solutions for hemophilia and rare blood disorders and it launched ESPEROCT® for hemophilia A treatment in February 2020.
• Roche is a Switzerland-based healthcare company serving the people since 1896. Hemlibra® developed by the company for the treatment of hemophilia A was granted approval by the US FDA in 2018.

Key Market Developments

• In May 2022, Precision Biologic launched the CRYOcheck Chromogenic Factor IX assay in Canada, the EU, Australia, and New Zealand after approval of health authorities in the respective countries. It was developed for the determination of FIX activity in patients with hemophilia B.
• In November 2022, UniQure announced the launch of the first hemophilia B gene therapy Hemgenix by 2023 with a price tag of $3.5 million. It is approved by the US government and is expected to launch by 2023.

Segmentation:

By Disease Type

• Hemophilia A
• Hemophilia B
• Others

By Therapy

• Replacement Therapy
• Gene Therapy
• Others (Immune Tolerance Induction Therapy etc.)

By Product Type

• Recombinant Coagulation Factor Concentrates
• Plasma-derived Coagulation Factor Concentrates
• Others (Desmopressin etc.)

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others